Abstract
Cytokine-Induced Killer (CIK) cells are CD3+ CD56+ effector cells endowed with T and NK cells phenotypic and functional properties, easy to expand in clinically relevant numbers and able to exert an antibody-dependent cell-mediated cytotoxicity (ADCC) if combined with monoclonal antibodies (mAbs). In the present study, we evaluated the enhancement of CIK cell antigen-specific lytic activity in combination either with the bispecific antibody (bsAb) HER2xCD3, or with the engineered mAb Trastuzumab (TRS) V90Lec13.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
